
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
UPDATE NOACS USE IN TREATMENT OF ATRIAL FIBRILLATION A REVIEW ATRICLE
Alifia Risma Fahmi* and Suharjono
Abstract Atrial fibrillation is a type of cardiac arrhythmia and it associated with increased risk for ischemic stroke. Vitamin K antagonists were used to reduce thromboembolic risk; however, these medications require therapeutic monitoring and increase risk of bleeding. Novel oral anticoagulants (NOACs) were use as alternative to vitamin K antagonists and several studies have showed the benefit of NOAC to decrease clotting as well as the risk of bleeding in over to vitamin K antagonists, such as warfarin. This study has found that NOACs are as effective as warfarin in reducing the risk of stroke through anticoagulation. Also, NOACs have a decreased risk of significant bleeding and other secondary risk effect. Keywords: NOACs, warfarin, Atrial Fibrillation, anticoagulant, novel oral anticoagulant, vitamin K antagonist. [Full Text Article] [Download Certificate] |
